katie sturino glp 1 For years, @katiesturino, the founder of @megababe, resisted GLP-1 medications that her doctor had been recommending to help improve her bloodwork. Eventually, the body acceptance advocate began the Influencers Saying They're On Ozempic

Zepbound vs Mounjaro: Head-to-Head Efficacy Comparison At a glance Active ingredient / tirzepatide (dual GIP/GLP-1 receptor agonist) in both products Manufacturer / Eli Lilly for both Zepbound and Mounjaro Zepbound FDA approval / November 2023 for chronic weight management Mounjaro FDA approval / May 2022 for type 2 diabetes (T2D) SURMOUNT-1 weight loss / 20.9% mean body-weight reduction at 72 weeks (15 mg dose) SURPASS-2 A1C reduction / up to 2.3 percentage points vs 1.86 for semaglutide 1 mg Dose range / 2.5 mg to 15 mg weekly subcutaneous injection for both brands Head-to-head trial / none exists

If reduced appetite from tirzepatide further decreases the small amount of B12-fortified foods these individuals consume, deficiency can develop rapidly

Skin will be flushed and warm immediately following the session, typically resolving within 24 hours

Services like Henry Meds, Shed, Ro, and others have streamlined the process of accessing GLP-1 drugs

In this Review, we discuss common reasons for GLP1R agonist and tirzepatide discontinuation and examine available evidence related to potential cardiometabolic consequences